Pevonedistat granted Breakthrough Therapy Designation for the treatment of higher-risk myelodysplastic syndromes (HR-MDS)

The designation for this investigational, first-in-class NEDD8-activating enzyme inhibitor is based on data from a Phase II study (Pevonedistat-2001) which evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with HR-MDS and other rare leukaemias.

Source:

Biospace Inc.